The Globe and Mail reports in its Tuesday edition that Stifel analyst Martin Landry is keeping his "buy" call on Lassonde Industries intact. The Globe's David Leeder writes in the Eye On Equities column that Mr. Landry tweaked his share target ahead by $5 to $255. Analysts on average target the shares at $254. Mr. Landry says in a note: "Lassonde reported strong Q2/25 revenues of $742-million, up 10 per cent organically. This strong organic growth rate is due to a solid performance in Canada where Lassonde benefits from the 'Buy Canadian' movement. The company's U.S. operations are also doing well with 10-per-cent volume growth leading to market share gains. As a result, management raised its revenue guidance for 2025, calling for revenues to increase slightly more than 10-per-cent year-over-year vs up 10 per cent previously. We see potential upside to management's guidance and model a revenue growth of 12.4-per-cent year-over-year, given the recent momentum in Canada. Orange concentrate appears excluded from U.S. tariffs applied to Brazilian exports, a sigh of relief for the company. Perhaps the only negative newsbite of the quarter was delays in the CAPEX related to the New Jersey facility due to permitting issues."